OMNIvance is a small molecule commercialized by Brii Biosciences, with a leading Phase I program in Acinetobacter Infections. According to Globaldata, it is involved in 3 clinical trials, of which 2 were completed, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of OMNIvance’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for OMNIvance is expected to reach an annual total of $29 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

OMNIvance Overview

Xeruborbactam is under development for the treatment of carbapenem-resistant infectious diseases including Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter infections. It is administered by intravenous route. The drug candidate is a combination of QPX7728 and beta lactamase inhibitor. The drug candidate acts by targeting beta lactamase.

Brii Biosciences Overview

Brii Biosciences is a biotechnology company that develops and commercializes medicines to treat central nervous systems and infectious diseases. It is investigating BRII-835 (VIR-2218) and BRII-179 (VBI-2601) against Hepatitis B virus; BRII-658 targeting multidrug-resistant TB (MDR-TB) mycobacteria; and BRII-636 (QPX-7728), BRII-672 (QPX-7831) and BRII-693 (QPX-9003) to treat infections caused due to multidrug-resistant gram-negative bacteria (MDR-GNB). The company is also evaluating BRII-732 and BRII-778 against human immunodeficiency virus (HIV); BRII-196 and BRII-198 targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); BRII-296 for paranoid personality disorder and major depressive disorder (MDD). The company has operations in China and the US. Brii Biosciences is headquartered in Shanghai, China.

The operating loss of the company was CNY4,189.9 million in FY2021, compared to an operating loss of CNY1,281.8 million in FY2020. The net loss of the company was CNY4,163.9 million in FY2021, compared to a net loss of CNY1,189.6 million in FY2020.

For a complete picture of OMNIvance’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.